To The Moon

1. $Upwork Inc.(UPWK)$ Surges 17.15% After Beating Q2 Expectations and Raising Profit Outlook on AI Growth Opportunity

Upwork shares are up over 19% after the platform for freelancers reported better-than-expected Q2 results and raised its full-year profit outlook.

Upwork reported a profit per share of $0.10 on revenue of $168.6 million, surpassing analysts' expectations for earnings and revenue. The strong financial performance indicated that the company is performing well and gaining traction in its marketplace.

Adjusted EPS: $0.10 vs. $0.00

Revenue: $168.6 mln vs. $162.5 mln

Upwork raised its full-year profit forecast, expecting adjusted EPS in the range of $0.36 to $0.39, which is significantly higher than the consensus estimate of $0.26. This upward revision shows confidence in the company's future growth prospects and potential for increased profitability.

Roth MKM analysts hiked the price target by $1 to $13 per share on the Buy-rated UPWK stock.

Goldman Sachs analysts also lifted the price target as they believe the Q2 results demonstrate solid execution on efficiency initiative & AI theme in a stable macro environment.

2. $Teva Pharmaceutical(TEVA)$ Surges 11.58% on Strong Q2 Results Fueled by Austedo and Uzedy Success

 Teva stock surged 11.58% on the back of strong second-quarter results driven by the success of its drugs Austedo and Uzedy.

Austedo, used to treat tardive dyskinesia, saw a remarkable 51% increase in sales in North America, reaching $308 million. Uzedy, a newly launched schizophrenia treatment, also contributed to the positive performance. Although Uzedy sales were not reported, the drug's recent U.S. launch added to the overall growth.

Teva's earnings of 56 cents per share on $3.88 billion in sales beat analysts' expectations. 

Adjusted EPS: $56 cents vs. 53 cents

Revenue: $3.88 bln vs. $3.71 bln

For the year, Teva raised the low end of its sales outlook. The company now expects $15 billion to $15.4 billion in full-year sales. Teva stock analysts had called for adjusted earnings of $2.26 per share and $15 billion in sales.

3. $T2 Biosystems(TTOO)$ +54.29%: Candida Auris Test Might Become A Potential Game-Changer

T2 Biosystems has faced a fundamental problem for a long time. Their systems and tests work well, but there hasn't been a compelling or significant reason for anyone to purchase them.

The introduction of the Candida Auris test could be a game-changer for T2 Biosystems, as it offers a compelling reason for people to purchase their machines.

The Centers for Disease Control and Prevention (CDC) has declared Candida Auris an emerging threat, and the FDA has provided a license pathway, making it more likely that demand for the test will increase.

T2 Biosystems has developed Candida Auris test and received "breakthrough device" status from the US Food and Drug Administration (FDA) for its Candida Auris molecular diagnostic blood test.

 How do you view the top movers?

Leave your comments to win tiger coins!

Rewards

• All valid comments on the following post will receive 5 Tiger Coins.

• The First 10 and Last 10 Commentator with qualified comments will receive another 10 Tiger Coins.